Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed EBIT Margin for 5 consecutive years, with 337.93% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin changed N/A year-over-year to 337.93%, compared with a TTM value of 535.89% through Sep 2025, up 163077.0%, and an annual FY2024 reading of 2385.63%, up 819747.0% over the prior year.
  • EBIT Margin was 337.93% for Q3 2025 at Autolus Therapeutics, down from 292.58% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1971.96% in Q1 2022 and bottomed at 379320.0% in Q4 2024.
  • Average EBIT Margin over 4 years is 49085.8%, with a median of 555.04% recorded in 2024.
  • The sharpest move saw EBIT Margin crashed -500199bps in 2023, then surged 264630bps in 2024.
  • Year by year, EBIT Margin stood at 1971.96% in 2022, then crashed by -636bps to 10567.73% in 2023, then plummeted by -3489bps to 379320.0% in 2024, then surged by 100bps to 337.93% in 2025.
  • Business Quant data shows EBIT Margin for AUTL at 337.93% in Q3 2025, 292.58% in Q2 2025, and 726.34% in Q1 2025.